NYSEAMERICAN:ATNMActinium Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Actinium Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.21 +0.01 (+4.91 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$0.21Now: $0.21▼$0.2250-Day Range N/A52-Week Range$0.16Now: $0.21▼$0.41Volume4.04 million shsAverage Volume4.21 million shsMarket Capitalization$64.76 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.50, Actinium Pharmaceuticals has a potential upside of 602.6% from its current price of $0.21.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesActinium Pharmaceuticals has received 311 “outperform” votes. (Add your “outperform” vote.)Underperform VotesActinium Pharmaceuticals has received 188 “underperform” votes. (Add your “underperform” vote.)Community SentimentActinium Pharmaceuticals has received 62.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote “Outperform” if you believe ATNM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webwww.actiniumpharmaceuticals.com Phone+1-646-6773875Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees30 Outstanding Shares303,344,000Market Cap$64.76 million Next Earnings Date6/5/2020 (Estimated) OptionableOptionable AMEX:ATNM Rates by TradingView Receive ATNM News and Ratings via Email Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Actinium Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Actinium Pharmaceuticals. When is Actinium Pharmaceuticals' next earnings date? Actinium Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, June 5th 2020. View our earnings forecast for Actinium Pharmaceuticals. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) announced its quarterly earnings data on Monday, March, 16th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' earnings history. What price target have analysts set for ATNM? 2 brokerages have issued twelve-month target prices for Actinium Pharmaceuticals' stock. Their forecasts range from $1.50 to $1.50. On average, they expect Actinium Pharmaceuticals' stock price to reach $1.50 in the next year. This suggests a possible upside of 602.6% from the stock's current price. View analysts' price targets for Actinium Pharmaceuticals. Has Actinium Pharmaceuticals been receiving favorable news coverage? News headlines about ATNM stock have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Actinium Pharmaceuticals earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutActinium Pharmaceuticals. Are investors shorting Actinium Pharmaceuticals? Actinium Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,400,000 shares, a drop of 47.2% from the April 30th total of 2,650,000 shares. Based on an average daily volume of 4,230,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.9% of the company's stock are sold short. View Actinium Pharmaceuticals' Current Options Chain. Who are some of Actinium Pharmaceuticals' key competitors? Some companies that are related to Actinium Pharmaceuticals include MediGene (MDG1), Oncolytics Biotech (ONC), CorMedix (CRMD), Senesco Technologies (ELOX), CorMedix (CRMD), Cohbar (CWBR), 22nd Century Group (XXII), Ampliphi Biosciences (APHB), Altimmune (ALT), Predictive Technology Group (PRED), Ibio (IBIO), Orgenesis (ORGS), Circassia Pharmaceuticals (CIR), AquaBounty Technologies (AQB) and Novoheart (NVH). View all competitors. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Opko Health (OPK), TransEnterix (TRXC), Tandem Diabetes Care (TNDM), Cancer Genetics (CGIX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Align Technology (ALGN). Who are Actinium Pharmaceuticals' key executives? Actinium Pharmaceuticals' management team includes the following people: Mr. Sandesh C. Seth, Chairman & CEO (Age 55)Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)Dr. Mark S. Berger, Chief Medical Officer (Age 64)Mr. Anil Kapur, Chief Commercial Officer (Age 50) What is Actinium Pharmaceuticals' stock symbol? Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM." Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.15%), Sabby Management LLC (0.20%) and PNC Financial Services Group Inc. (0.05%). Company insiders that own Actinium Pharmaceuticals stock include Dale L Ludwig, Sandesh Seth and Steve O'loughlin. View institutional ownership trends for Actinium Pharmaceuticals. Which institutional investors are selling Actinium Pharmaceuticals stock? ATNM stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC, and PNC Financial Services Group Inc.. View insider buying and selling activity for Actinium Pharmaceuticals. Which institutional investors are buying Actinium Pharmaceuticals stock? ATNM stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Dale L Ludwig, Sandesh Seth, and Steve O'loughlin. View insider buying and selling activity for Actinium Pharmaceuticals. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Actinium Pharmaceuticals' stock price today? One share of ATNM stock can currently be purchased for approximately $0.21. How big of a company is Actinium Pharmaceuticals? Actinium Pharmaceuticals has a market capitalization of $64.76 million. Actinium Pharmaceuticals employs 30 workers across the globe. What is Actinium Pharmaceuticals' official website? The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com. How can I contact Actinium Pharmaceuticals? Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875. This page was last updated on 6/2/2020 by MarketBeat.com Staff
